Digital RESI September Investor Panel

Monday, September 13
10:00 – 11:00 AM EDT

Medical Devices

Bringing the Next Generation of Medical Devices to Market

Investing in medical devices has become more complex with time. While standard medical devices are still a mainstay, there are an increasing amount of combination devices, software-enabled devices and diagnostic devices that require investors to have expertise in multiple sectors. Panelists may discuss topics such as:

  • The benefits vs. risks of devices that cross sectors
  • Regulatory challenges
  • Amount/type of data they want to see before investing

Panelists will discuss how to meet the challenges of raising financing for a new device and advise startups on how to make the investment case for their novel technology. Panelists will also explore what technology areas are of top interest to them and how a startup can make themselves stand out in the crowd.

Monday, September 13
12:00 – 1:00 PM EDT

Seed Funds

Investing in the Earliest Stage Companies

Investing in the earliest stages comes with a high risk and a potentially high reward. Whether investing in a therapeutics or digital health company, seed investors have to make difficult decisions with a lot less data than other investors. The panelists will discuss topics such as:

  • How much proof-of-concept validation is needed for seed funding
  • What increased benefit is needed to mitigate the increased risk
  • What is unique in the structure of seed-stage deals (convertible notes vs straight equity)
  • Does the early stage of the company lead investors to take a more active role

Many investors prefer to wait for later stages due to the decreased risk of failure. Those investors who are willing to take the risk of seed-stage investment will share their approach and selection criteria when assessing early-stage companies.

Monday, September  13
2:00 – 3:00 PM EDT

Big Pharma

Pipeline Strategy for Preclinical and Early Clinical Assets

In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines. This panel brings together speakers from various big pharma companies discussing topics such as:

  • How big pharma sources assets
  • The evaluation and investment process
  • Key factors of interest
  • How early-stage big pharma is willing to look

These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.

Tuesday, September 14
10:00 – 11:00 AM EDT

Asia Cross Border

Latest Perspectives from Asian Groups on Investments and Partnerships

These days, seeking capital from Asia-headquartered investors, pharmaceuticals, and other strategic partners may seem like nothing new. Many groups continue to expand into geographies outside of Asia to set up new offices, establishing open innovation departments, etc. However, companies based in the USA, Europe, and other parts of the world without any proper connection to Asia still find themselves struggling to engage with the right groups.

This panel will discuss the following topics and more:

  • How are Asian markets and regulatory hurdles different from those of the USA/Europe?
  • What do cross-border investors seek in companies outside of Asia? How are they similar or different to their viewpoint on domestic companies?
  • How has COVID positively or negatively impacted the decision making process?
  • Aside from the effects of COVID on the industry, will cross-border investment activities continue to increase?
  • What are some common mistakes investors see from entrepreneurs, and how can they be avoided?

Panelists will discuss how they have been evaluating opportunities in the midst of the COVID pandemic and what the future holds for cross-border activities in the industry. Panelists will also uncover general topics such as navigating the Asian market and the regulatory challenges associated with market entry, how to approach Asian investors and strategic groups, and more.

Tuesday, September 14
12:00 – 1:00 PM EDT

Tales from the Road

Biotech & Medtech CEOs Speak About Their Fundraising Journey

The industry has quickly adapted to a “new normal” – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges.

This panel will discuss the following topics and more:

  • What are some of the greatest challenges entrepreneurs have faced especially during the pandemic, and how were they overcome?
  • How did entrepreneurs identify investors that fit their technology?
  • What are some misconceptions entrepreneurs had about the early-stage investment landscape?

Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.

Tuesday, September 14
2:00 – 3:00 PM EDT

Mental & Behavioral Health

Investing in Technologies that Help Manage Well-Being

With COVID having affected the lives of many across the globe, triggering feelings of fear, stress, uncertainty, and more, the importance of technologies that address mental & behavioral health disorders continues to be recognized by many. Despite the number of people affected by mental & behavioral disorders, this continues to be a stigmatized area and patients easily find themselves lacking the resources and support they need.

This panel will discuss the following topics and more:

  • Why is investing in mental & behavioral health so important?
  • Has COVID changed investors’ perspectives on mental & behavioral health in any way?
  • What are the biggest problems in the current mental & behavioral health landscape (i.e. collecting and consolidating patient data, access to care, identifying appropriate interventions for each disease, etc.)
  • How can the industry continue to reduce the stigma associated with mental & behavioral disorders?

Panelists will highlight the representation of mental & behavioral health within the industry through various investor types, including hospital and healthcare systems. Panelists will discuss how to meet the challenges of raising financing for a highly stigmatized—though prevalent—area and advise startups on how to make the investment case for their novel technology. Panelists will explore what trends in mental & behavioral health are of top interest, its future outlook, and global impact.

Wednesday, September 15
10:00 – 11:00 AM EDT

Corporate VC

Novel Approaches on Corporate Innovation & Their Value-Add

Corporate venture capital firms are an important source of capital for early-stage companies. Many major pharmaceuticals and large corporations have set up a corporate investment arm to identify early-stage companies. Strategically and financially driven in varying degrees, the implications of working with CVCs are huge, as the resources, network, and guidance provided by the CVC and the associated parent company are incredibly valuable to an entrepreneur who is actively growing their business.

This panel will discuss the following topics and more:

  • How are CVCs different from traditional VCs?
  • How strategically vs. financially are CVCs driven, and how does this affect their decision-making process?
  • How closely does the CVC communicate with the parent company?
  • What does working with a CVC entail?

Panelists will discuss each of their investment mandates and how they relate to corporate interests, and how they have been sourcing opportunities during COVID. Panelists may also explore current trending areas of interest, and what they see as emerging fields in the near future.

Wednesday, September 15
12:00 – 1:00 PM EDT

Angels & Family Offices

How Do Family Offices & Angels View Seed & Series A Rounds?

Angel investors are a mainstay in the earliest financing rounds, and many consider Family Offices as the holy grail of investors. These groups share many similarities, and can work in synergy to help their portfolio companies advance. This panel will cover topics such as:

  • What are the similarities and differences between Angels and Family Offices?
  • What are the benefits of working with each group?
  • How does investing personal money change the way Angels and Family Offices act from the traditional VC?

A startup looks to many different kinds of investors when fundraising, and understanding the fundamental differences between groups can improve the success of their approach. Angels and Family Offices frequently invest early on, and can shape the way a company develops. Panelists will discuss how best to approach them and engage their interest.